Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to 60.45%.

  • Enanta Pharmaceuticals' EBIT Margin rose 783700.0% to 60.45% in Q4 2025 from the same period last year, while for Dec 2025 it was 109.08%, marking a year-over-year increase of 566300.0%. This contributed to the annual value of 130.65% for FY2025, which is 492700.0% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported EBIT Margin of 60.45% as of Q4 2025, which was up 783700.0% from 121.56% recorded in Q3 2025.
  • Enanta Pharmaceuticals' EBIT Margin's 5-year high stood at 60.45% during Q4 2025, with a 5-year trough of 221.7% in Q1 2023.
  • Moreover, its 5-year median value for EBIT Margin was 152.03% (2021), whereas its average is 152.93%.
  • Per our database at Business Quant, Enanta Pharmaceuticals' EBIT Margin crashed by -1045300bps in 2021 and then skyrocketed by 828200bps in 2025.
  • Enanta Pharmaceuticals' EBIT Margin (Quarter) stood at 109.99% in 2021, then dropped by -16bps to 127.25% in 2022, then crashed by -52bps to 193.78% in 2023, then increased by 28bps to 138.82% in 2024, then surged by 56bps to 60.45% in 2025.
  • Its last three reported values are 60.45% in Q4 2025, 121.56% for Q3 2025, and 103.16% during Q2 2025.